Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 16/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14386894 | 1.00 | CCR2 (0.60) | CCR2NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL14387099 | 0.85 | CCR2 (0.59) | CCR2ALDH1A1MAPT | |
| SCHEMBL5326776 | 0.85 | CCR2 (0.59) | CCR2ALDH1A1MAPT | |
| SCHEMBL14430068 | 0.83 | CCR2 (0.57) | CCR2ALDH1A1MAPT | |
| SCHEMBL5324936 | 0.83 | CCR2 (0.57) | CCR2ALDH1A1MAPT | |
| SCHEMBL5367022 | 0.83 | CCR2 (0.57) | CCR2ALDH1A1MAPT | |
| SCHEMBL5322741 | 0.83 | CCR2 (0.57) | CCR2ALDH1A1MAPT | |
| SCHEMBL5362732 | 0.81 | CCR2 (0.55) | CCR2NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL5322704 | 0.81 | CCR2 (0.55) | CCR2NPC1ALDH1A1RAB9AMAPT | |
| SCHEMBL5325949 | 0.81 | CCR2 (0.57) | CCR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | claimed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | claimed |
| WO-2007130712-A1 | SUBSTITUTED DIPIPERIDINE AS CCR2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | JANSSEN PHARMACEUTICA, NV (BE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | JANSSEN PHARMACEUTCA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197590-A1 | SUBSTITUTED DIPIPERIDINE CCR2 ANTAGONISTS | CCR2, CCR1, CCR5 | CCR2 1/4885NPC1 677/4885ALDH1A1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.